AR122587A1 - Compuestos de imidazopiridazina y sus usos - Google Patents
Compuestos de imidazopiridazina y sus usosInfo
- Publication number
- AR122587A1 AR122587A1 ARP210101581A ARP210101581A AR122587A1 AR 122587 A1 AR122587 A1 AR 122587A1 AR P210101581 A ARP210101581 A AR P210101581A AR P210101581 A ARP210101581 A AR P210101581A AR 122587 A1 AR122587 A1 AR 122587A1
- Authority
- AR
- Argentina
- Prior art keywords
- compounds
- azabicyclo
- methyl
- formula
- imidazopyridazine compounds
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Dental Preparations (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Se describen compuestos de fórmula (1), métodos de uso de los compuestos para inhibir la actividad de ALK2 y composiciones farmacéuticas que comprenden dichos compuestos. Los compuestos son útiles para tratar, prevenir o mejorar enfermedades o trastornos asociados con la actividad de ALK2, como el cáncer. Reivindicación 1: Un compuesto de la fórmula (1) o una sal farmacéuticamente aceptable de este, caracterizado porque: R¹ se selecciona de 1-etil-1H-imidazol-4-ilo y 4-metil-2H-1,2,3-triazol-2-ilo; y R² se selecciona de (1R,5S)-3-(tetrahidro-2H-piran-4-il)-3-azabiciclo[3.1.0]hexan-1-ilo y 2-metil-2-azabiciclo[2.2.2]octano.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063038410P | 2020-06-12 | 2020-06-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR122587A1 true AR122587A1 (es) | 2022-09-21 |
Family
ID=76971994
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210101581A AR122587A1 (es) | 2020-06-12 | 2021-06-10 | Compuestos de imidazopiridazina y sus usos |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US11840546B2 (es) |
| EP (1) | EP4165051A1 (es) |
| JP (1) | JP2023530088A (es) |
| KR (1) | KR20230025434A (es) |
| CN (1) | CN115956081A (es) |
| AR (1) | AR122587A1 (es) |
| AU (1) | AU2021288107A1 (es) |
| BR (1) | BR112022025191A2 (es) |
| CA (1) | CA3184811A1 (es) |
| CL (1) | CL2022003453A1 (es) |
| CO (1) | CO2022017969A2 (es) |
| EC (1) | ECSP22093652A (es) |
| IL (1) | IL298248A (es) |
| MX (1) | MX2022015493A (es) |
| PE (1) | PE20230491A1 (es) |
| TW (1) | TW202214660A (es) |
| WO (1) | WO2021252781A1 (es) |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL202623B1 (pl) | 2000-06-28 | 2009-07-31 | Smithkline Beecham Plc | Sposób wytwarzania drobno zmielonego preparatu substancji leczniczej, drobno zmielona substancja lecznicza wytworzona tym sposobem i zawierająca ją kompozycja farmaceutyczna |
| PE20090506A1 (es) * | 2007-07-26 | 2009-05-28 | Novartis Ag | DERIVADOS DE IMIDAZO-[1,2-b]-PIRIDAZIN COMO INHIBIDORES DE ALK5 Y/O ALK4 |
| ES2393430T3 (es) | 2007-10-17 | 2012-12-21 | Novartis Ag | Derivados de imidazo[1,2-A]-piridina útiles como inhibidores de ALK |
| US8987273B2 (en) | 2010-07-28 | 2015-03-24 | Bayer Intellectual Property Gmbh | Substituted imidazo[1,2-B]pyridazines |
| EP2463289A1 (en) | 2010-11-26 | 2012-06-13 | Almirall, S.A. | Imidazo[1,2-b]pyridazine derivatives as JAK inhibitors |
| US20140171434A1 (en) | 2011-01-11 | 2014-06-19 | Bayer Pharma Aktiengessellschaft | Substituted imidazopyridines and imidazopyridazines and the use thereof |
| US9682983B2 (en) | 2013-03-14 | 2017-06-20 | The Brigham And Women's Hospital, Inc. | BMP inhibitors and methods of use thereof |
| WO2017070089A1 (en) | 2015-10-19 | 2017-04-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| MD3377488T2 (ro) | 2015-11-19 | 2023-02-28 | Incyte Corp | Compuși heterociclici ca imunomodulatori |
| TW201726623A (zh) | 2015-12-17 | 2017-08-01 | 英塞特公司 | 作為免疫調節劑之雜環化合物 |
| MX2018007774A (es) | 2015-12-22 | 2018-11-09 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores. |
| AR108396A1 (es) | 2016-05-06 | 2018-08-15 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| ES2905980T3 (es) | 2016-05-26 | 2022-04-12 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| CN109890819B (zh) | 2016-06-20 | 2022-11-22 | 因赛特公司 | 作为免疫调节剂的杂环化合物 |
| EP3484866B1 (en) | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| EP3504198B1 (en) | 2016-08-29 | 2023-01-25 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| CN109952293A (zh) | 2016-09-14 | 2019-06-28 | 范德比尔特大学 | Bmp信号转导的抑制、化合物、组合物及其用途 |
| MX2019002951A (es) | 2016-09-15 | 2019-09-11 | Armstrong World Ind Inc | Sistema de techo con movimiento aereo. |
| ES2899402T3 (es) | 2016-12-22 | 2022-03-11 | Incyte Corp | Derivados de piridina como inmunomoduladores |
| WO2018119263A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds derivatives as pd-l1 internalization inducers |
| PE20191532A1 (es) | 2016-12-22 | 2019-10-23 | Incyte Corp | Compuestos heterociclicos como inmunomoduladores |
| WO2018119236A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
| JP7303108B2 (ja) | 2016-12-22 | 2023-07-04 | インサイト・コーポレイション | 免疫調節剤としての二環式複素芳香環化合物 |
| LT3558990T (lt) | 2016-12-22 | 2022-12-27 | Incyte Corporation | Tetrahidroimidazo[4,5-c]piridino dariniai kaip pd-l1 internalizavimo induktoriai |
| WO2018136634A1 (en) | 2017-01-18 | 2018-07-26 | Vanderbilt University | Fused heterocyclic compounds as selective bmp inhibitors |
| WO2018165569A1 (en) | 2017-03-10 | 2018-09-13 | Rutgers, The State University Of New Jersey | Therapeutic compounds and methods |
| MX2021007426A (es) | 2018-12-20 | 2021-09-08 | Incyte Corp | Compuestos de imidazopiridazina e imidazopiridina como inhibidores de cinasa-2 de tipo receptor de activina. |
-
2021
- 2021-06-10 US US17/344,255 patent/US11840546B2/en active Active
- 2021-06-10 IL IL298248A patent/IL298248A/en unknown
- 2021-06-10 EP EP21743321.8A patent/EP4165051A1/en active Pending
- 2021-06-10 BR BR112022025191A patent/BR112022025191A2/pt unknown
- 2021-06-10 CA CA3184811A patent/CA3184811A1/en active Pending
- 2021-06-10 KR KR1020237000999A patent/KR20230025434A/ko active Search and Examination
- 2021-06-10 PE PE2022002872A patent/PE20230491A1/es unknown
- 2021-06-10 CN CN202180041015.0A patent/CN115956081A/zh active Pending
- 2021-06-10 AR ARP210101581A patent/AR122587A1/es unknown
- 2021-06-10 AU AU2021288107A patent/AU2021288107A1/en active Pending
- 2021-06-10 MX MX2022015493A patent/MX2022015493A/es unknown
- 2021-06-10 TW TW110121255A patent/TW202214660A/zh unknown
- 2021-06-10 WO PCT/US2021/036839 patent/WO2021252781A1/en unknown
- 2021-06-10 JP JP2022576034A patent/JP2023530088A/ja active Pending
-
2022
- 2022-12-06 CL CL2022003453A patent/CL2022003453A1/es unknown
- 2022-12-09 EC ECSENADI202293652A patent/ECSP22093652A/es unknown
- 2022-12-12 CO CONC2022/0017969A patent/CO2022017969A2/es unknown
-
2023
- 2023-10-31 US US18/385,742 patent/US20240083918A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN115956081A (zh) | 2023-04-11 |
| US20210388003A1 (en) | 2021-12-16 |
| JP2023530088A (ja) | 2023-07-13 |
| CL2022003453A1 (es) | 2023-05-26 |
| ECSP22093652A (es) | 2023-02-28 |
| EP4165051A1 (en) | 2023-04-19 |
| CO2022017969A2 (es) | 2023-02-27 |
| US20240083918A1 (en) | 2024-03-14 |
| IL298248A (en) | 2023-01-01 |
| TW202214660A (zh) | 2022-04-16 |
| AU2021288107A1 (en) | 2022-12-15 |
| US11840546B2 (en) | 2023-12-12 |
| PE20230491A1 (es) | 2023-03-23 |
| BR112022025191A2 (pt) | 2023-03-07 |
| MX2022015493A (es) | 2023-03-21 |
| CA3184811A1 (en) | 2021-12-16 |
| KR20230025434A (ko) | 2023-02-21 |
| WO2021252781A1 (en) | 2021-12-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR119731A1 (es) | Inhibidores del inflamasoma nlrp3 | |
| BR112022012641A2 (pt) | Compostos tricíclicos substituídos | |
| AR120109A1 (es) | Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores | |
| CL2023002090A1 (es) | Inhibidores de kras tricíclicos fusionados | |
| CO2021015698A2 (es) | Moduladores de thr-β y métodos de uso de estos | |
| CO2022008997A2 (es) | Compuestos tricíclicos sustituidos | |
| AR112834A1 (es) | Derivados de rapamicina | |
| AR116115A1 (es) | Dimetil amino azetidina amidas como inhibidores de jak | |
| AR116283A1 (es) | Inhibidores del sarcómero cardíaco | |
| AR118768A1 (es) | Derivados de pirimidina como inhibidores de las cinasas jak | |
| AR097773A1 (es) | Compuesto y composición farmacéuticamente aceptable, útil para tratar afección o trastorno mediano por actividad quinurenina 3-mono-oxigenasa | |
| CL2023000387A1 (es) | Derivados de dioxoloisoquinolinona novedosos y uso de los mismos | |
| ECSP23095674A (es) | Análogos de triazolo pirimidina para el tratamiento de enfermedades relacionadas con la inhibición de la helicasa recq del síndrome de werner (wrn) | |
| AR119322A1 (es) | Compuestos derivados de 1h-pirido[1,2-a]pirazina como inhibidores de magl | |
| CO2024001285A2 (es) | Compuestos tricíclicos como inhibidores de kras | |
| AR126854A1 (es) | Compuestos macrocíclicos para el tratamiento de cáncer | |
| AR097772A1 (es) | Compuesto y composición farmacéuticamente aceptable, útil para tratar afección o trastorno mediado por actividad quinurenina-3-monooxigenasa | |
| AR122587A1 (es) | Compuestos de imidazopiridazina y sus usos | |
| AR120170A1 (es) | Derivados de 2-azaspiro[3,4]octano como agonistas de m4 | |
| AR128622A1 (es) | Inhibidores de la cinasa mek | |
| PE20211454A1 (es) | Derivados de imidazopiridina y su uso como medicamento | |
| AR093395A1 (es) | Triazoles sustituidos con alcoholes secundarios como inhibidores de pde10 | |
| AR127235A1 (es) | Pirazoloquinolinas inhibidoras de kras | |
| AR124189A1 (es) | Compuestos y procedimientos de uso de los mismos | |
| AR125479A1 (es) | Inhibidores de il4i1 y métodos de uso |